BioSpace News Archive

Anavex Life Sciences Corp. announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, “Establishing Mutually Beneficial Collaborations,” at the World EPA Congress 2021 event on Thursday, April 15th at 8:55 a.m. EDT.

Kamada Ltd., a plasma-derived biopharmaceutical company, announced an amendment to the GLASSIA® [Alpha1-Proteinase Inhibitor ] license agreement with Takeda.

Evogene Ltd., a leading computational biology company announced that it will hold virtual investor and analyst days, in both Hebrew and English, via Zoom webinars.

OpSens Inc., a medical device cardiology-focused company, announced it has been awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the U.S.

Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 April 2021 , at 14:00 hours CEST at Kjelsåsveien 168 B 0884 Oslo.

- NURTEC® ODT achieved preliminary net product revenue of approximately $43.8 million for the first quarter of 2021 - Launch to date net product revenue for NURTEC ODT is approximately $107.4 million, with over 500,000 prescriptions filled since launch in March 2020

Medable Inc, the leading cloud platform for patient-centered drug development, today announced the hiring of Dr. Pamela Tenaerts as Chief Scientific Officer.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference

E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and simultaneous killing of cancer cells in both in vitro and in vivo models